Ding Y, Zhou Y, Lai Q, Li J, Gordon V, Diaz F G
Department of Neurological Surgery, Wayne State University School of Medicine, Lande Medical Research Building, Room 48, 550 E Canfield St., Detroit, MI 48201, USA.
Brain Res. 2001 Oct 12;915(2):210-7. doi: 10.1016/s0006-8993(01)02852-9.
Poly(ADP-ribose) polymerase (PARP) can initiate an energy-consuming and inefficient repair cycle following cerebral ischemia/reperfusion by transferring ADP ribose units to nuclear proteins eventually leading to cellular dysfunction and neuronal death. 3-Aminobenzamide (3-AB) is a selective inhibitor of PARP that can significantly reduce brain damage after focal ischemia in rats and displays a low toxicity in vivo. The goals of this study were to determine if inhibiting PARP with 3-AB has a long-term neuroprotective effect and if functional outcome improves in rats following focal ischemia and treatment with 3-AB. Focal ischemia was induced by a 2-h occlusion of the middle cerebral artery (MCA), using an intraluminal filament. Motor functions were evaluated from 5 to 28 days after reperfusion in four groups of rats: stroke without treatment; stroke treated with 3-AB at doses of 15 mg/kg, stroke treated with 3-AB at doses of 55 mg/kg; and the non-ischemic control rats. Functional behaviors were tested by a series of motor function tasks (foot placing, parallel bar crossing, rope and ladder climbing), as well as a neurological examination. Infarct volume of stroke brain in the same rat was determined by Nissl staining 28 days after surgery. Comparison of the untreated stroke group (n=11) and the treated stroke groups indicates that impairment of motor function was significantly (P<0.001) reduced by administration of 3-AB at doses of 15 mg/kg (n=9) or 55 mg/kg (n=10). Neurological outcome was also improved significantly (P<0.001). Infarct volume was significantly (P<0.01) reduced in both treated groups. Long-term neuroprotection following ischemia/reperfusion injury to the brain can be obtained by administration of a PARP inhibitor. The motor tests employed in this study can be used as sensitive, objective and reproducible measurements of functional impairment in rats following an ischemic stroke.
聚(ADP - 核糖)聚合酶(PARP)可在脑缺血/再灌注后启动一个耗能且低效的修复循环,通过将ADP核糖单位转移至核蛋白,最终导致细胞功能障碍和神经元死亡。3 - 氨基苯甲酰胺(3 - AB)是PARP的选择性抑制剂,可显著减轻大鼠局灶性缺血后的脑损伤,且在体内显示出低毒性。本研究的目的是确定用3 - AB抑制PARP是否具有长期神经保护作用,以及在大鼠局灶性缺血并接受3 - AB治疗后功能结局是否改善。使用腔内细丝闭塞大脑中动脉(MCA)2小时诱导局灶性缺血。在四组大鼠再灌注后5至28天评估运动功能:未治疗的中风组;用15mg/kg剂量3 - AB治疗的中风组;用55mg/kg剂量3 - AB治疗的中风组;以及非缺血对照大鼠。通过一系列运动功能任务(足放置、平行杠穿越、绳索和梯子攀爬)以及神经学检查来测试功能行为。术后28天通过尼氏染色确定同一大鼠中风脑的梗死体积。未治疗的中风组(n = 11)与治疗的中风组的比较表明,给予15mg/kg(n = 9)或55mg/kg(n = 10)剂量的3 - AB可显著(P < 0.001)减轻运动功能损害。神经学结局也显著改善(P < 0.001)。两个治疗组的梗死体积均显著(P < 0.01)减小。给予PARP抑制剂可获得脑缺血/再灌注损伤后的长期神经保护作用。本研究中采用的运动测试可作为大鼠缺血性中风后功能损害的敏感、客观且可重复的测量方法。